Göran Lerenius

Business and legal advisor

Role in PharmNovo: Chairman of the board.

Born: 1950.

Education: Juris Dr degree 1976 from University of Lund.

Other current appointments: Senior Advisor to HealthCap.

Work experience: AstraZeneca 32 years; Lagerlöfs Law Firm (today Linklaters) 1½ years. Associate at the law firm Linklaters (Lagerlöf at that time) in Stockholm for almost two years before joining Astra AB as Legal Counsel in 1980. Göran was General Counsel in 1984–1999 and Company Secretary of Astra AB 1988–1999. When Astra Zeneca Ltd was formed in 1999 Göran served as General Counsel Pharmaceuticals through 2008 and finished his career with the company as Deputy General Counsel IP Litigation until retirement early 2012. Göran was a Non-Executive Director of Astra Merck, Inc in the US 1994–1998.

Holdings: 40 000 shares.

Member of:

Board of directors

Latest news

View all

October 10, 2024

PharmNovo at the LSX Nordic Congress

PharmNovo attended the LSX Nordic Congress in Copenhagen 8-9 October and Per von Mentzer, CEO presented PN6047, a unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. Being one of 68 companies that have recently been awarded by EIC for up to 17.5 MEUR (2.5 MEUR grant and up to 15 MEUR equity) from a total of 969 applicants is a strong validation of the potential of the phase II ready asset PN6047 and of PharmNovo. Take the opportunity to listen to the presentation here:

July 17, 2024

17.5 MEUR blended funding from EIC

PharmNovo is very pleased to announce that we have been awarded a 2.5 MEUR grant and an opportunity for up to 15 MEUR equity investment from the European Innovation Council (EIC) for innovative pain treatment. The equity part being contingent on investments of equal amounts from co-investors.

PharmNovo presenting at the Global Forum

June 5, 2024

PharmNovo presenting at the Global Forum

On May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.

March 21, 2024

Positive final Phase I results

The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.